Estimating the global and regional impact of introducing typhoid conjugate vaccination schedules: a modelling study
BACKGROUND: In 2018, WHO recommended single-dose typhoid conjugate vaccines (TCVs) for typhoid-endemic countries. Emerging evidence of waning immunity has raised questions about optimal vaccination age and booster doses. A follow-up multi-model study evaluated vaccination schedules, focusing on booster strategies. Here, we expand findings from one of four modelling groups, estimating the global and regional health impact of TCV schedules. METHODOLOGY: We developed an agent-based typhoid transmission model using the open-source Starsim toolbox. The model captures subclinical and acute infections, chronic carriers, and natural and vaccine-derived immunity, with age- and sex-specific parameters and outcomes. The model was calibrated to three incidence archetypes (medium, high, and very high) and two vaccine-derived immunity durations (fast and slow waning). Countries were mapped to archetypes based on national typhoid burden. We compared no vaccination with four strategies: routine vaccination at 9 months, 9 months with a booster at 5 years, 2 years, and 5 years, each with a catch-up campaign. Cases, deaths, and DALYs averted were estimated globally and across GBD super-regions over 10 years. RESULTS: Globally, up to 29.5 million cases and 8.2 million DALYs could be averted with routine vaccination at 9 months plus a 5-year booster. Earlier vaccination and longer-lasting immunity generally increased impact. Under fast waning, vaccination at 2 years averted more cases and DALYs than vaccination at 9 months or 5 years, particularly in high-incidence settings where burden was greatest among children aged 2-<5 years. Boosters provided additional benefits, especially with fast waning. South Asia accounted for the largest share of global impact, followed by Sub-Saharan Africa. CONCLUSION: TCV could avert substantial typhoid burden. The optimal age for a single dose depends on how quickly protection wanes, and boosters add benefit where waning is rapid. Better evidence on the protection duration, and country-specific analyses, are needed to guide schedule choices.
Authors
- Nick Scott (ORCID: https://orcid.org/0000-0002-9213-0798)
- Romesh Abeysuriya (ORCID: https://orcid.org/0000-0002-9618-6457)
- Alina M. Muellenmeister (ORCID: https://orcid.org/0009-0005-9712-0141)
Institutions
- Burnet Institute (AU)
Publication Details
- Journal
- Vaccine
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1016/j.vaccine.2026.129352
- Primary Topic
- Salmonella and Campylobacter epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00